MILNER THERAPEUTICS SYMPOSIUM 2022


Tuesday 28th June
Cambridge, UK and Online

Milner Therapeutics Symposium 2022

Symposium Overview

Our Annual Symposium is an opportunity for scientists from academia and industry to discuss the latest academic and pre-clinical research and how it could be applied in the pharma and biotech industry to develop new treatments. It is our key networking event for Milner Therapeutics Institute partner organizations.

This year’s event will be held on Tuesday 28th June 2022, at West Road Concert Hall in Cambridge. This will be our first ever Hybrid Symposium, where we will welcome up to 500 delegates in person and also live-stream the event for those who are overseas or unable to attend.

Registration to the Symposium is free, and is open to academics and Milner affiliated companies only. Please do not register if your organisation is not currently affiliated with the Milner Therapeutics Institute. Instead, please email us at symposium@milner.cam.ac.uk to discuss eligibility.

REGISTER NOW » 

PROGRAMME »

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Information for Attendees

The Milner Therapeutics Symposium 2022 will be our first hybrid symposium.

The in-person event will be held at West Road Concert Hall in Cambridge, and sessions will also be live-streamed to an online platform. Delegates will be asked to choose their ticket type (live or online) when registering for the Symposium.

Themes

Oncology   ·   CNS therapeutics   ·   Infectious Disease  ·   Emerging technologies   ·   Disease-relevant models in target discovery

Speakers

Simon Boulton (Artios Pharma and The Francis Crick Institute), Lori Passmore (MRC Laboratory of Molecular Biology), Ravindra Gupta (Cambridge Institute of Therapeutic Immunology and Infectious Disease), Kristian Helin (Institute of Cancer Research), Giulia Biffi (CRUK Cambridge Institute, University of Cambridge), Matthias Zilbauer (Department of Paediatrics, University of Cambridge), Richard Hargreaves (Bristol Myers Squibb) and Andras Lakatos (Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge)

You can find out more about our speakers further down this page.

Panel Session

Shaping the future of interdisciplinary interactions

Chaired by Kristin-Anne Rutter (Cambridge University Health Partners)
Michael Anstey (Cambridge Innovation Capital) – Jamie Blundell (Institute for the Early Detection of Cancer, University of Cambridge) – Victoria Higgins (GlaxoSmithKline) –  Andy Neely (University of Cambridge) – Jeroen Verheyen (Semarion)

You can find out more about the panel session further down this page.

Posters

We are keen to invite posters from both academia and industry, to be presented in person and/or digitally as part of our hybrid Symposium.
The deadline to submit poster abstracts is Friday, 3rd June. To submit a poster abstract, please click here.
If you’ve already submitted an abstract, we will contact you with a decision after the submission deadline.

Meet the Consortium Session

Registered attendees (academics and affiliated partners) can request a short meeting with our pharma companies in the Milner Therapeutics Consortium during the morning of the Symposium (10:30-11:45am). These will be short non-confidential discussions held with a Milner Board member from the company of interest, aimed at identifying collaborative opportunities.

Please complete this form only after you have registered. Attendees will be informed of meetings that have been confirmed ahead of the Symposium.

Affiliated Company Overview Videos

Milner Affiliated Companies are invited to submit an overview video for display on the online Symposium platform. Please email symposium@milner.cam.ac.uk to request the video specifications and upload link.

Eligibility

Please do not register if your organisation is not currently affiliated with the Milner Therapeutics Institute. Please email us at symposium@milner.cam.ac.uk to discuss eligibility.

Speakers

 

“Targeting the DNA damage response”

Simon Boulton

 Artios Pharma and
The Francis Crick Institute

Regulation of DNA interstrand crosslink repair”

Lori Passmore

MRC Laboratory of Molecular Biology

Novel Targets for the Treatment of Acute Myeloid Leukaemia

Kristian Helin

Institute of Cancer Research

“No Cancer Cell is an Island: why the microenvironment matters during pancreatic cancer progression and treatment”

Giulia Biffi

CRUK Cambridge Institute
University of Cambridge

SARS-CoV-2 Variants

Ravindra Gupta

Cambridge Institute of Therapeutic Immunology & Infectious Disease

Human gut organoids as translational research tools to study epigenetics in IBD

Matthias Zilbauer

Department of Paediatrics
University of Cambridge

Putting the CNS back in BMS

Richard Hargreaves

Bristol Myers Squibb

“Human ALS brain organoids: from cell type-specific pathogenesis to therapeutic strategies”

Andras Lakatos

Department of Clinical Neurosciences
University of Cambridge

Panel Discussion: Shaping the future of interdisciplinary interactions

A Q&A with the experts. Chaired by Kristin-Anne Rutter, Executive Director of Cambridge University Health Partners.
“Targeting the DNA damage response”

Kristin-Anne Rutter

Executive Director
Cambridge University Health Partners

“Targeting the DNA damage response”

Jeroen Verheyen

Co-founder and CEO
Semarion

“No Cancer Cell is an Island: why the microenvironment matters during pancreatic cancer progression and treatment”

Michael Anstey

Partner
Cambridge Innovation Capital

“Targeting the DNA damage response”

Victoria Higgins

Senior Director, UK Academic Alliance Management
GlaxoSmithKline

Mo Zhao

Andy Neely

Pro-Vice-Chancellor for Enterprise and Business Relations
University of Cambridge

Regulation of DNA interstrand crosslink repair”

Jamie Blundell

Institute for Early Detection of Cancer
University of Cambridge

With thanks to our Symposium sponsors

Platinum Sponsor:

Bronze Sponsors: